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Relationship Between Serum Level of Fibroblast Growth Factor-23
(FGF-23) and Calcium and Phosphate Metobolism of Patients with
Chronic Kidney Disease
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Objective: To investigate the relationship between serume level of fibro-
blast growth factor-23 (FGF-23) and calcium and phosphate of patients
with chronic kidney disease.
Methods: Intact FGF-23 and 1,25(OH)2 vitamin D3 were detected by enzyme-
linked immunosorbent assay (ELISA) in CKD 151 patients with various degree
of renal function and fourteen healthy controls, at the same time, some
other parameters including creatinine, serum phosphate, calcium, parathyr-
iod hormone, uric acid and alkaline phosphatese were measured. Further,
the relationship between FGF-23 and other biochemical variables was
analysed.
Results: (1) The level of serum FGF-23 was gradually elevated at CKD stage
1,2e3,4e5, there were significant difference in CKD stage 2e3 and 4e5
compared respectively with normal controls (P < 0.01), and in CKD stage
4e5 compared with CKD stage 1 and 2e3 (P < 0.01). (2) In the CKD stage
1e5 the level of serum FGF-23 by Pearson relativity analysis was significantly
correlated positively with creatinine (r Z 0.97, P < 0.01), phosphate
(r Z 0.65, P < 0.01), and parathyroid hormone (r Z 0.536, P < 0.01). The
level of serum FGF-23 by Pearson relativity analysis was significantly corre-
lated negatively with eGFR (r Z 0.578, P < 0.01), 1,25(OH)2 vitamin D3
(r Z 0.586, P < 0.01). (3) In the CKD stage 1e5, creatinine, 1,25(OH)2
vitamin D3 and parathyroid hormone were significant variables that influ-
enced the level of serum FGF-23 in multiple regression analysis.
Conclusion: FGF-23 concentrations were gradually elevated in three groups
of patients with CKD, serum phosphorus, 1,25(OH)2D3, intact PTH and creat-
inine are the major regulators that influenced FGF-23.0051
Table 2 151例CKD患者FGF-23与相关变量的相关分析
NZ 151 r-value P-value
CREA 0.971 <0.01
eGFR -0.578 <0.01
1.25(OH)2D3 -0.586 <0.01
Ca -0.327 <0.01
P 0.650 <0.01
Ca*P 0.477 <0.01
UA 0.173 0.033
ALP 0.143 0.079
PTH 0.536 <0.01http://dx.doi.org/10.1016/j.hkjn.2015.09.1480051
Table 1 CKD1-5期患者血清各指标的比较(x  s)
CREA eGFR FGF-23 1.25
(mmol/l) (ml/min/1.73 m2) (pg/ml) (pg/
正常对照组 43.8  2.71 118.81  5.42 20.82  1.20 595
NZ 14 (x  s)
CKD1期 69.82  13.20 112.62  8.18 71.19  8.26 546
NZ 22 (x  s)
CKD2-3期 139.90  35.19 58.97  16.96) 81.73  13.23) 531
NZ 47 (x  s)
CKD4-5期 440.74
 331.36)6
15.75
 7.67)6
198.05
 111.68)6
409
 1NZ 82 (x  s)
方差分析 F 28.67 593.98 38.46 19.9
P <0.01 <0.01 <0.01 <0.
*和对照组比较，P<0.05；6与CKD1、CKD2-3比较，P<0.05.0052
Function of Reduced Blood Pressure by Compound a-Ketoacid in Non-
dialysis Patients with CKD Stage 3e5
Li SongYang
Jinan Central Hospital, Shanghai, China
Objective: Evaluate the effect of blood pressure-lowering by a-ketoacid in
patients with CKD.
Methods: Selected non-dialysis patients who had hypertension of CKD 3e5
grade, except three cases. All of the patients had taken anti-hypertension
medicine over 3 months. They were treated for an average of 34.5  38.7
months, but SBP was still  140 mmHg and DBP  90 mmHg. A total of 102
patients were included in the statistical analysis. Among them, 61 were
male and 41 were female. Mean age was 70.78  12.34 years (range, 27 to
86 years). 51 cases were CKD stage 3, 31 cases were CKD stage 4, 20 cases
were CKD stage 5. Mean duration of chronic renal insufficiency was
32.7  33.3 months (range, 4 to 120 months). Mean duration of hypertension
was 232.4  174.4 months (range, 4 to 636 months). A low protein diet
(0.6 g/kg.d) and compound a-ketoacid (2.52 g, tid) were given to all pa-
tients. At the same time, the anti-hypertension drugs were not changed dur-
ing the study. After 6 months, statistical analysis was used to compare blood
pressure, PTH and renal function changes before and after treatment.
Results: In 102 cases, total efficiency rate was 83.3%. Mean systolic blood pres-
sure was 163.4  15.8 mmHg before treatment and 137.8  14.8 mmHg after
treatment. Mean diastolic blood pressure was 87.9 12.9 mmHg before treat-
ment and 77.0  9.6 mmHg after treatment (P < 0.01). Mean systolic blood
pressure decreased 25.9  14.8 mmHg and diastolic blood pressure decreased
10.8  9.7 mmHg. There were statistically significant differences. PTH had
markedly decreased after treatment, but there was no statistically significant
differences in renal function before and after treatment.
Conclusion: Low protein diet combining compound a-ketoacid may help to
control hypertension in CKD patients.http://dx.doi.org/10.1016/j.hkjn.2015.09.149
0055
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Objective: Chronic obstructive pulmonary disease (COPD) increases all-
cause mortality and cardiovascular (CV) events in general population. How-
ever, rare study investigates the death and CV risks among chronic kidney(OH)2D3 Ca P Ca*P PTH
ml) (mmol/L) (mmol/L) (mmol2/L2) (pg/l)
.11  10.03 2.27  0.19 1.15  0.13 2.61  0.43 33.81  1.47
.78  102.66 2.27  0.17 1.23  0.15 2.79  0.41 38.59  3.29
.12  114.74 2.24  0.22 1.35  0.15) 3.02  0.40 68.14  30.13
.03
30.51)6
2.10  0.21 1.81
 0.13)6
3.80  0.43 225.41
 172.42)6
7.22 209.01 26.44 69.22
01 <0.01 <0.01 <0.01 <0.01
